What’s the current market cap for Maze Therapeutics, Inc. stock?

Maze Therapeutics, Inc. (MAZE) has a market cap of $1.4B as of May 26, 2026.

What is the P/E ratio for Maze Therapeutics, Inc. stock?

The price to earnings (P/E) ratio for Maze Therapeutics, Inc. (MAZE) stock is 0 as of May 26, 2026.

Does Maze Therapeutics, Inc. stock pay dividends?

No, Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders as of May 26, 2026.

When is the next Maze Therapeutics, Inc. dividend payment date?

Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders.

What is the beta indicator for Maze Therapeutics, Inc.?

Maze Therapeutics, Inc. (MAZE) does not currently have a Beta indicator.

Buy Maze Therapeutics, Inc. stock | $MAZE Share Price

13:30

15:10

16:45

18:25

20:00

About Maze Therapeutics, Inc.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Ticker

$MAZE

Sector

Health

Primary listing

NASDAQ

Employees

141

Headquarters

South San Francisco, United States

Website

www.mazetx.com

MAZE Metrics

BasicAdvanced

$1.4bn

-$2.49

Bulls say / Bears say

Maze Therapeutics reported positive topline results from the Phase 2 HORIZON trial of MZE829, with a 35.6% mean uACR reduction at week 12. This marks the first clinical proof-of-concept in broad APOL1-mediated kidney disease and supports progress toward a pivotal program.

The company's available cash, cash equivalents, and marketable securities as of March 31, 2026, along with proceeds from the April 2026 registered offering and a $20 million milestone payment from Shionogi & Co., Ltd., are expected to fund operations into 2029 under the current plan.

Maze entered a senior secured term loan facility of up to $200 million with Hercules Capital on February 4, 2026, securing an initial $40 million tranche and extending its financial runway into 2031, while replacing its prior Banc of California facility.

Despite recording $20 million in license revenue in Q1 2026, Maze reported a net loss of $24.2 million, highlighting continued unprofitability during early-stage clinical development.

The company posted a $39.1 million negative operating cash flow in Q1 2026, reflecting high cash burn from clinical trial and platform development expenses.

Maze's $150 million registered offering of 5.54 million shares at $23.50 per share, announced in April 2026, could dilute existing shareholders and weigh on near-term valuation.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MAZE

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Despite recording $20 million in license revenue in Q1 2026, Maze reported a net loss of $24.2 million, highlighting continued unprofitability during early-stage clinical development.

The company posted a $39.1 million negative operating cash flow in Q1 2026, reflecting high cash burn from clinical trial and platform development expenses.

Maze's $150 million registered offering of 5.54 million shares at $23.50 per share, announced in April 2026, could dilute existing shareholders and weigh on near-term valuation.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.